Skip to main content

home

OVERVIEW
Our unique Guangzhou-Israel Biotechnology Fund (GIBF) creates added value for Israeli, European and American companies looking to expand in China.

With years of life sciences expertise, private equity investment experience, local knowledge based on over a decade of activity in China, and numerous foreign companies already established in China, GIBF serves as an invaluable strategic investor and partner in China with a proven ability and track record of conducting multi-center clinical trials in top-tier Chinese hospitals, providing the resources and networks for securing successful NMPA submissions, commercializing products and developing manufacturing capacity to satisfy both local and global demand.

OUR STRATEGY
Enabling value creation by investing in Chinese subsidiaries of foreign companies active in the biomedical outside China
GIBF partners with selected companies from Israel, Europe and the USA to establish new JVs in the Chinese market, enabling the foreign companies to control and manage their new subsidiaries as the majority shareholders.
PORTFOLIO
Companies' Overview
Partnering with top-tier international life sciences companies offering innovative solutions to Chinese healthcare needs.

COMPANY

InMode (NASDAQ: INMD) (Exit)

SECTOR

Medical Device

COMPANY

G-Medical (NASDAQ: GMVD)

SECTOR

Medical Device

COMPANY

CarboFix

SECTOR

Medical Device
OUR PEOPLE
Meet Our Management
Where global leaders in life sciences meet local talents to achieve cross-border investments and companies' formation.
DR. YEHOSHUA(SHUKI) GLEITMAN
Founding Partner and Chairman
PROF. SHLOMO NOY
Founding Partner and Chief Medical Officer
AVNER LUSHI
Founding Partner and CEO
CARL GENG
Founding Partner and General Manager
Latest
News

VIEW ALL

Latest
News
Bioversys

BioVersys Announces Last Patient Last Visit in BV100 Phase 2 Clinical Trial in Ventilator Associated Bacterial Pneumonia (VABP) and Provides a Business Update

(16 October, 2024) BioVersys's BV100 Phase 2 preliminary results suggest BV100 is generally safe and well tolerated and showed strong initial signs of efficacy in VABP patients.

投资组合向右箭头
silexion

Silexion Therapeutics Reports Breakthroughs From SIL-204 Preclinical Studies

(1 October, 2024) Latest preclinical studies reveal significant improvements in stability, efficacy, and KRAS targeting range for next-generation siRNA candidate SIL-204.

投资组合向右箭头
silexion

Silexion Therapeutics Announces Significant New Data from Phase 2 Trial of LODER™ in Non-Resectable Pancreatic Cancer

(24 September, 2024)New analysis from Silexion's Phase 2 trial of LODER shows a 56% objective response rate (ORR) and 67% resectability improvement in non-resectable pancreatic cancer

投资组合向右箭头